Uveitis News and Research

RSS

Uveitis is an inflammation of the uvea. The uvea is the front part of the eye. It includes the iris, which is the colored part of the eye, and the parts right next to and behind the iris. Uveitis may hurt a lot of parts of the eye. It may last as long as six weeks, or it may last a shorter time.

COVID-19 patients' eyes and tears can be infected with SARS-CoV-2

A new study investigates the presence of SARS-CoV-2 in tears and eye secretions and describes the ocular symptoms in patients with COVID-19.

31 Oct 2021

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Uveitis is an inflammation of the eye and is a common extra-articular manifestation associated with juvenile idiopathic arthritis (JIA). It can cause vision-threatening complications, and if left uncontrolled may even lead to blindness.

18 Jun 2021

International coalition develops classification criteria for 25 subtypes of uveitis

An international coalition of eye researchers used machine learning to develop classification criteria for 25 of the most common types of uveitis, a collection of over 30 diseases characterized by inflammation inside the eye.

7 Jun 2021

Horizontal transmission route is responsible for HTLV-1 uveitis

Human T-cell lymphotropic virus type-1 (HTLV-1) is a retrovirus similar to human immunodeficiency virus (HIV) and has mostly been thought to be transmitted vertically (mother-to-child), or horizontally (sexually or parenterally (e.g. via blood transfusion)).

28 Apr 2021

New approach to cancer immunotherapy may prevent autoimmunity

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments.

19 Mar 2021

New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments

The American College of Rheumatology will preview the 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis at ACR Convergence, the ACR's annual meeting.

6 Nov 2020

Inflammation in the eye after COVID-19

A new study published on the preprint server medRxiv shows the occurrence of ocular pathology in the period of recovery following COVID-19. This throws more light on the occurrence of inflammation in people recovering from COVID-19.

25 Sep 2020

Therapeutic derived from turmeric shows promise in treating canine ocular condition

Researchers at Texas A&M University have produced a therapeutic derived from turmeric, a spice long-praised for its natural anti-inflammatory properties, that shows promise in decreasing ocular inflammation in dogs suffering from uveitis, an inflammation of the eye that leads to pain and reduced vision.

4 Sep 2020

Study uncovers dual role for molecule involved in autoimmune eye disease

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.

23 Jul 2020

New study to evaluate drug combination treatment for uveitis

Two in 10,000 people are at risk of serious sight loss from a form of eye inflammation known as uveitis. A new clinical research study, led by the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (UHBW), will evaluate a drug combination treatment for the eye disease thanks to funding of £2.5 million by the National Institute for Health Research (NIHR).

13 May 2020

Fight for Sight funded researcher develops gene therapy approach for glaucoma

A Fight for Sight funded researcher from the University of Bristol has used gene editing techniques to successfully demonstrate a gene therapy for glaucoma in the lab, in results published in Molecular Therapy in March.

11 Mar 2020

Two uveitis drugs perform similarly in a head-to-head clinical trial

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

11 Sep 2019

Scientists use AI to improve diagnosis and monitoring of rare eye condition

Fight for Sight is funding research by scientists from universities and hospitals in Birmingham and London using artificial intelligence to extract ‘hidden’ information from retinal images of patients with a rare eye condition called birdshot uveitis.

23 Jul 2019

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Today, the American College of Rheumatology, in partnership with the Arthritis Foundation, released two guidelines on juvenile idiopathic arthritis.

30 Apr 2019

Microglia play vital role in regulating neuroinflammation, research shows

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system--including the retina of the eye--serve as "gatekeepers," or biosensors and facilitators, of neuroinflammation in a preclinical model of autoimmune uveitis.

23 Apr 2019

Ebola survivors in Liberia have higher prevalence of health issues, study shows

Survivors of Ebola virus disease in Liberia had a higher prevalence of certain health issues--including uveitis (eye redness and pain), abdominal, chest, neurologic, and musculoskeletal abnormalities upon physical exam--when compared to a control group of household and community members who did not have a history of EVD, according to findings from an ongoing study published in the New England Journal of Medicine.

8 Mar 2019

Researchers find a class of drug that could be promising treatment for uveitis

Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness.

2 Nov 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Uveitis News and Research

Further Reading

COVID-19 patients' eyes and tears can be infected with SARS-CoV-2

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

International coalition develops classification criteria for 25 subtypes of uveitis

Horizontal transmission route is responsible for HTLV-1 uveitis

New approach to cancer immunotherapy may prevent autoimmunity

New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments

Inflammation in the eye after COVID-19

Therapeutic derived from turmeric shows promise in treating canine ocular condition

Study uncovers dual role for molecule involved in autoimmune eye disease

New study to evaluate drug combination treatment for uveitis

Fight for Sight funded researcher develops gene therapy approach for glaucoma

Two uveitis drugs perform similarly in a head-to-head clinical trial

Scientists use AI to improve diagnosis and monitoring of rare eye condition

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Microglia play vital role in regulating neuroinflammation, research shows

Ebola survivors in Liberia have higher prevalence of health issues, study shows

Researchers find a class of drug that could be promising treatment for uveitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News